Acinetobacter baumani and Pseudomonas aeruginosa drug susceptibility after bacteriological analysis of sputum in patients mechanically ventilated in ICUSource: Eur Respir J 2003; 22: Suppl. 45, 450s Year: 2003
Acinetobacter baumanii and Stenotrophomonas maltophilia are associated with lower airway infections in tracheostomised children and young adults. Source: International Congress 2017 – New insights into paediatric respiratory infections Year: 2017
Risk factors and outcomes of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa: a clinical case-control study Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes Year: 2017
Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD. Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond Year: 2020
Clinical and microbiological characteristics of Pseudomonas aeruginosa isolates from patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 58s Year: 2005
Significance of positive Stenotrophomonas maltophilia culture in acute respiratory tract infection Source: Eur Respir J 2005; 25: 911-914 Year: 2005
Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors Source: Eur Respir J 2010; 35: 598-615 Year: 2010
Multidrug resistant acinetobacter baumannii in ventilator associated pneumonia: Prevalence and predictors of mortality Source: International Congress 2014 – ICU outcomes, sepsis and infections Year: 2014
Direct LAMP assay from clinical sample for carbapenem resistant A. baumannii Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014
Aetiopathogenesis of VAP revisited Source: Eur Respir Mon 2011; 53: 1-10 Year: 2011
Association of acinetobacter baumannii respiratory isolates with hospital outcomes in ventilated patients Source: Eur Respir J 2006; 28: Suppl. 50, 785s Year: 2006
Ventilator-associated pneumonia (VAP) pathogenic microorganisms eradication and persistence during antimicrobial therapy Source: Annual Congress 2013 –Recent developments in pneumonia Year: 2013
Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia Source: Eur Respir J 2007; 29: 548-560 Year: 2007
Comparative results of preemptive therapies in mechanically ventilated patients with carbapanem-resistant Acinetobacter baumannii (CRAB) Source: International Congress 2017 – Hospital-acquired infections: from prevention to treatment Year: 2017
Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients Source: Eur Respir J, 52 (2) 1701190; 10.1183/13993003.01190-2017 Year: 2018
Antibiotic sensitivity of pseudomonas aeroginosa isolates of respiratory secretions taken from ICU patients of the NRITLD Source: Eur Respir J 2004; 24: Suppl. 48, 641s Year: 2004
Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia Source: Eur Respir J 2009; 34: 1148-1158 Year: 2009
Potential treatment for nosocomial respiratory strains of extreme drug resistant acinetobacter baumanii Source: Eur Respir J 2007; 30: Suppl. 51, 410s Year: 2007
Pseudomonas aeruginosa colonisation in patients without bronchiectasisSource: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014